Clinical Trial

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-11-10; most recent amendment 2026-04-24.
Status change: Not Yet Recruiting → Recruiting 2023-12-11
Trial Details
NCT Number NCT06132828
Lead Sponsor Zhejiang Doer Biologics Co., Ltd.
Conditions Solid Tumor
Enrollment 216 participants
Start Date 2023-11-27
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-27